年长的MRD与年轻的MUD在50岁以上的AML缓解期的患者中使用移植后环胺
Simona Piemontese1, Myriam Labopin2, Goda Choi3
1Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Hospital, Milan, Italy. piemontese.simona@hsr.it.
Leukemia
|July 24, 2024
概括
对于接受干细胞移植的老年急性髓性白血病 (AML) 患者来说,当使用中等/高强度调节时,与老年匹配的相关捐赠者 (MRD) 相比,更年轻的匹配的非相关捐赠者 (MUD) 改善了结果. 结果与低强度调节的捐赠者类型无关,结果相似.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 移植医学 移植医学
背景情况:
- 全源性造血干细胞移植 (allo-HSCT) 越来越多地用于老年急性髓性白血病 (AML) 患者.
- 老年患者往往有较老的匹配相关捐赠者 (MRD),促使对匹配无关捐赠者 (MUD) 的调查作为替代方案.
研究的目的:
- 为了比较老年AML患者 (年龄大于50岁) 在第一次完全缓解 (CR1) 的allo-HSCT的结果,使用年轻的MUDs (<40岁) 与老年MRDs (>50岁) 相比.
- 评估供体年龄对结局的影响,并与移植后环胺 (PTCy) 和移植条件强度 (TCI) 相结合.
主要方法:
- 在CR1中连续345名AML患者进行了回顾性分析,这些患者接受了首次allo-HSCT.
- 患者按TCI得分 (低,中,高) 和捐赠者类型 (年轻的MUD与老的MRD) 分层.
- 使用多变量分析来评估移植对宿主无疾病,无复发生存期 (GRFS),非复发死亡率 (NRM) 和复发发病率 (RI).
主要成果:
- 在TCI中等/高组中,与较老的MRD相比,年轻的MUD与显著更好的GRFS,较低的NRM和较低的RI有关.
- 对于接受低TCI条件的患者来说,供体类型没有显著影响结果.
- 在所有移植协议中使用PTCy.
结论:
- 较年轻的MUD (<40岁) 优于较老的MRD (>50岁) 对于较老的AML患者 (>50岁) 在CR1中接受TCI中间/高条件和PTCy的allo-HSCT.
- 在TCI低的调节方案中,供体选择可能不那么关键.
- 这些发现对接受allo-HSCT的老年AML患者的供体选择策略有影响.
相关概念视频
Bone Marrow Sampling and Transplants
318
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
318
Tissue Transplantation
352
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
352
Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K


